Immunomedics, Inc. (IMMU) To Provide Clinical Trial Updates On Solid-Tumor Antibody-Drug Conjugates At Cancer Conference
3/31/2014 9:20:23 AM
MORRIS PLAINS, N.J., March 31, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 – 9, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by